Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Heart failure (HF) is a common, costly and treatable clinical syndrome.1 2 Over 920 000 people in England are living with the condition and 3%–4% of the National Health Service (NHS) budget is spent on HF services.3 Large clinical trials have established the clinical and cost-effectiveness of disease-modifying drugs and device therapies in improving quality of life, reducing hospitalisations and increasing survival for patients with HF with reduced ejection fraction.4 5 The same prognostic benefit was not seen in HF with preserved ejection fraction but diagnosis remains important to explain patients’ symptoms. In both types of HF, diuretics are effective in reducing fluid overload and exercise-based cardiac rehabilitation is beneficial once patients are stable.
Timely and accurate diagnosis is key to accessing appropriate, evidence-based treatment. People with HF initially experience symptoms of breathlessness, fatigue and ankle swelling which progress over time.1 2 Guidelines recommend that people presenting to primary care with suspected HF should have a natriuretic peptide blood test. If the level is raised, referral for echocardiography and specialist assessment is needed to confirm the diagnosis of HF or determine an alternative cause for the person’s symptoms. However, a first diagnosis of HF is often made in hospital which may be distressing for patients, costly to the health service and usually denotes progression to a later stage of disease. Most patients with HF have seen their general practitioner (GP) prior to receiving a diagnosis and …
Contributors CT wrote the editorial.
Funding CT is funded by a National Institute for Health Research (NIHR) Academic Clinical Lectureship at the University of Oxford. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Competing interests Roche Diagnostics have provided NT-proBNP testing equipment to CT’s research team but did not have any influence on study design, conduct or reporting.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.